MECOM and chronic granulomatous disease: The use of the SFFV long terminal repeat (LTR), which expresses well in myeloid cells, may have driven the expansion of MDS1-EVI1, PRDM16, or SETBP1 integration containing myeloid cells observed in patients treated for chronic granulomatous disease using a similar approach [4], [5].